Adjuvant Comparison and Characterization (HIV)

佐剂比较和表征（HIV）

• 批准号: 10834856
• 负责人: BALI PULENDRAN
• 金额: $ 178.1万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10834856
• 关键词: Adjuvant; Antibody Response; Antigens; Encapsulated; Fingerprint; Gel; Goals; HIV; HIV vaccine; Immune; Immune response; Immunologics; Infection; Learning; Mucous Membrane; Side; Tissues; Vaccines; Work; clinically relevant; lipid nanoparticle; neutralizing antibody; nonhuman primate; programs; vaccine development

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms. A major challenge for HIV vaccine development is learning how to induce robust and durable antibody responses that protect against mucosal infection. A critical step on the path to overcoming this challenge are developing adjuvants that appropriately stimulate robust and durable immune responses. The goal of this project is to assess the impact of 3 different adjuvants on enhancing the magnitude and durability of neutralizing antibody responses against HIV Env.

佐剂比较和表征(ACC)计划的目标是支持佐剂与临床相关疫苗/抗原平台相结合的并列比较，并建立通过不同机制发挥作用的佐剂的系统和组织特异性免疫学特征(“免疫指纹”)。艾滋病毒疫苗开发的一个主要挑战是学习如何诱导强大和持久的抗体反应，以防止粘膜感染。在克服这一挑战的道路上，关键的一步是开发适当刺激强大和持久免疫反应的佐剂。该项目的目标是评估3种不同佐剂在增强针对HIV Env的中和抗体反应的幅度和持久性方面的影响。